| # | Title | Journal | Year | Citations |
|---|
| 1 | Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer | JAMA Oncology | 2019 | 303 |
| 2 | Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study | Annals of Oncology | 2019 | 110 |
| 3 | Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer | Clinical Cancer Research | 2020 | 77 |
| 4 | Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC) | Annals of Oncology | 2017 | 71 |
| 5 | LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer | Annals of Oncology | 2021 | 56 |
| 6 | ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). | Journal of Clinical Oncology | 2015 | 51 |
| 7 | ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). | Journal of Clinical Oncology | 2015 | 43 |
| 8 | CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study | Annals of Oncology | 2017 | 40 |
| 9 | Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study | Annals of Oncology | 2022 | 28 |
| 10 | Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC | Journal of Thoracic Oncology | 2020 | 27 |
| 11 | Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) | Annals of Oncology | 2017 | 17 |
| 12 | 141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials | Journal of Thoracic Oncology | 2016 | 16 |
| 13 | Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM) | Annals of Oncology | 2016 | 15 |
| 14 | Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC) | Annals of Oncology | 2017 | 14 |
| 15 | Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study | Annals of Oncology | 2016 | 12 |
| 16 | A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors | OncoTargets and Therapy | 2018 | 11 |
| 17 | nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2 | Frontiers in Oncology | 2018 | 10 |
| 18 | LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study | Annals of Oncology | 2019 | 10 |
| 19 | FIRST-LINE TREATMENT OF INHL OR MCL PATIENTS WITH BR OR R-CHOP/R-CVP: RESULTS OF THE BRIGHT 5-YEAR FOLLOW-UP STUDY | Hematological Oncology | 2017 | 7 |
| 20 | Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab | Gynecologic Oncology | 2020 | 5 |
| 21 | Two Phase III Studies Evaluating Ceritinib in Patients (Pts) with Anaplastic Lymphoma Kinase (Alk)-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc): Ascend-4 and Ascend-5 | Annals of Oncology | 2014 | 3 |
| 22 | Phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx) | Annals of Oncology | 2016 | 3 |
| 23 | Results From a Phase I Study of MK-1308 (ANTI–CTLA-4) Plus Pembrolizumab in Previously Treated Advanced Small Cell Lung Cancer | Annals of Oncology | 2019 | 3 |
| 24 | 334P Lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients: Updated phase II results and dose selection | Annals of Oncology | 2020 | 3 |
| 25 | 1020O A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours | Annals of Oncology | 2020 | 3 |
| 26 | Progression-free survival (PFS) and site of first progression in HER2+ metastatic breast cancer (MBC) patients (pts) with (w) or without (w/o) brain metastases: A pooled analysis of tucatinib phase I studies | Annals of Oncology | 2017 | 2 |
| 27 | Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3) | Annals of Oncology | 2018 | 2 |
| 28 | 1199P Dose modification for the management of CNS adverse events in the phase III CROWN study of lorlatinib in non-small cell lung cancer (NSCLC) | Annals of Oncology | 2021 | 2 |
| 29 | 480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts) | Annals of Oncology | 2016 | 2 |
| 30 | Preliminary efficacy and safety of lorlatinib in patients (Pts) with ROS1-positive non-small cell lung cancer (NSCLC) | Annals of Oncology | 2017 | 1 |
| 31 | P2.07-058 First-In-Human Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, for Non-Small Cell Lung Cancer | Journal of Thoracic Oncology | 2017 | 1 |
| 32 | Final clinical results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/IV nonsquamous non-small cell lung cancer | Annals of Oncology | 2017 | 1 |
| 33 | 127TiP PROPEL: A phase I/II trial of bempegaldesleukin (NKTR-214) in combination with pembrolizumab (pembro) in patients (pts) with advanced solid tumours | Annals of Oncology | 2019 | 1 |
| 34 | 278MO cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients | Annals of Oncology | 2020 | 1 |
| 35 | 1793P RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC) | Annals of Oncology | 2020 | 1 |
| 36 | 128TiP HER2CLIMB-04: Phase II trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ unresectable locally-advanced or metastatic breast cancer with and without brain metastases | Annals of Oncology | 2021 | 1 |
| 37 | Prospective Validation of the FLIPI: Baseline Distribution and Correlates in Newly Diagnosed Follicular Lymphoma (FL) Patients from the US: First Report of the National LymphoCare Study. | Blood | 2005 | 1 |
| 38 | OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis (039) | Gynecologic Oncology | 2022 | 1 |
| 39 | Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study | Clinical Lung Cancer | 2023 | 1 |
| 40 | Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) previously treated with 2nd-generation ALK TKIs | Annals of Oncology | 2017 | 0 |
| 41 | A phase 1 study of oral LOXO 292 in adult patients with advanced solid tumors, including RET-fusion non-small cell lung cancer, medullary thyroid cancer and other tumors with increased RET activity | Annals of Oncology | 2017 | 0 |
| 42 | A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer | Annals of Oncology | 2017 | 0 |
| 43 | Anti-GITR agonist TRX518 in combination with gemcitabine in advanced solid cancers: Preliminary safety and efficacy from a multi-center phase Ib trial | Annals of Oncology | 2018 | 0 |
| 44 | Phase I study of the CTLA-4 inhibitor MK-1308 in combination with pembrolizumab in patients with advanced solid tumors | Annals of Oncology | 2018 | 0 |
| 45 | 181P The use of Ki67 testing and scoring in HR+, HER2- early breast cancer | Annals of Oncology | 2020 | 0 |
| 46 | 777TiP Phase I study of LYL797, a ROR1-targeted CAR T-cell therapy with genetic and epigenetic reprogramming for the treatment of advanced solid tumors | Annals of Oncology | 2022 | 0 |
